Introduction
Retatrutide (development code LY-3437943) is a novel triple hormone receptor agonist developed by Eli Lilly. It targets the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR) to provide comprehensive treatment for obesity and type 2 diabetes. The drug's clinical trial results were formally released in June 2023, with related studies published in multiple authoritative international medical journals, demonstrating exceptional therapeutic potential and broad application prospects.
Pharmacological Activity
Retatrutide's efficacy stems from its unique triple-target receptor agonist properties. By simultaneously acting on GIPR, GLP-1R, and GCGR, it regulates metabolic balance through multiple pathways:
GLP-1R activation: Promotes insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite.
GIPR activation: Enhances insulin secretion and sensitivity.
GCGR activation: Regulates blood glucose and reduces hepatic fat accumulation.
This multi-target synergy enables superior control of blood glucose, weight reduction, and metabolic improvement.
Mechanism of Action
Retatrutide operates through a sophisticated mechanism:
GLP-1R pathway: Stimulates insulin secretion from pancreatic β-cells while inhibiting glucagon release from α-cells, lowering blood glucose. It also acts centrally to suppress appetite and delay gastric emptying.
GIPR pathway: Amplifies insulin secretion/sensitivity, facilitating glucose utilization and storage.
GCGR pathway: Reduces hepatic gluconeogenesis and lipogenesis, further decreasing blood glucose and lipid levels.
This triple-axis coordination delivers unique advantages for treating obesity and type 2 diabetes.
Clinical Applications
Retatrutide is primarily indicated for:
Obesity: Demonstrates unprecedented weight loss efficacy. In Phase 2 trials, the 12 mg dose achieved 24.2% weight reduction over 48 weeks – among the highest drug-induced losses recorded. It concurrently improves blood pressure, lipids, and metabolic health.
Type 2 diabetes: Significantly lowers blood glucose and HbA1c levels, reduces insulin dependence, and enhances pancreatic function and insulin sensitivity.
Side Effects
Common adverse reactions include:
Gastrointestinal effects: Nausea, vomiting, diarrhea, abdominal pain (typically mild-moderate and dose-dependent).
Cardiovascular effects: Dose-dependent increase in heart rate (peaks early and stabilizes).
Long-term use may lead to tolerance and weight rebound. Close monitoring and dose adjustment are essential during treatment.
China
